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D6 is a scavenging-receptor for inflammatory CC
chemokines that are essential for resolution of in-
flammatory responses in mice. Here, we demonstrate
that D6 plays a central role in controlling cutaneous
inflammation, and that D6 deficiency is associated
with development of a psoriasis-like pathology in re-
sponse to varied inflammatory stimuli in mice. Exam-
ination of D6 expression in human psoriatic skin
revealed markedly elevated expression in both the
epidermis and lymphatic endothelium in “unin-
volved” psoriatic skin (ie, skin that was more than 8
cm distant from psoriatic plaques). Notably, this in-
creased D6 expression is associated with elevated in-
flammatory chemokine expression, but an absence of
plaque development, in uninvolved skin. Along with
our previous observations of the ability of epider-
mally expressed transgenic D6 to impair cutaneous
inflammatory responses, our data support a role for
elevated D6 levels in suppressing inflammatory chemo-
kine action and lesion development in uninvolved pso-
riatic skin. D6 expression consistently dropped in
perilesional and lesional skin, coincident with
1158development of psoriatic plaques. D6 expression in un-
involved skin also was reduced after trauma, indicative
of a role for trauma-mediated reduction in D6 expres-
sion in triggering lesion development. Importantly, D6
is also elevated in peripheral blood leukocytes in psori-
atic patients, indicating that upregulation may be a gen-
eral protective response to inflammation. Together our
data demonstrate a novel role for D6 as a regulator of
the transition from uninvolved to lesional skin in
psoriasis. (Am J Pathol 2012, 181:1158–1164; http://dx.doi.
org/10.1016/j.ajpath.2012.06.042)
Psoriasis is a common cutaneous inflammatory disorder1
with poorly understood pathogenesis. Although there is
evidence of a pre-psoriatic phenotype in “uninvolved”
psoriatic skin (ie, skin that is more than 8 cm distant from
psoriatic plaques),2,3 the factors regulating transition to
lesion development are unknown. Chemokines4 are es-
sential regulators of inflammatory leukocyte migration in
vivo, and are important for the development of a range of
inflammatory pathologies, including psoriasis.5,6 They
are therefore plausible central contributors to this transi-
tion event. Accordingly, their regulation is likely to affect
pathogenesis.5,6 We study the regulation of the resolution
of chemokine-driven inflammatory responses, and have
characterized an atypical chemokine receptor,7 D6 (a
7-transmembrane–spanning receptor) that is active both in
vitro and in vivo as a “scavenging receptor” for inflammatory
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cific for inflammatory CC chemokines, as it does not bind
homeostatic CC chemokines, CXC chemokines, or XC or
CX3C chemokines.7 D6 is expressed in lymphatic endothe-
lial cells12 in the skin, gut, and lung as well as in the syncy-
tiotrophoblast layer of the placenta.13,14 In addition, D6 is
expressed by subsets of peripheral blood leukocytes.15
Consistent with its chemokine-scavenging role, D6-defi-
cient mice are unable to efficiently resolve inflammatory
responses.16–19 In the context of the skin, treatment with the
phorbol ester TPA, induces an exaggerated inflammatory
response in D6-deficient mice that is not seen in wild-type
(WT) mice and that bears many similarities to psoriasis.16 In
addition, transgenic expression of D6 in the epidermis ac-
tively suppresses cutaneous inflammatory responses.20
This suggests a role for D6 in limiting overt cutaneous
chemokine action that might otherwise lead to development
of inflammatory disorders such as psoriasis.
In this study, we demonstrate a key role for D6 in reso-
lution of cutaneous inflammatory responses in mice. We
also show, for the first time, that D6 is overexpressed and
regulated in uninvolved psoriatic skin in a manner support-
ive of a role in suppressing psoriatic lesion development.
Materials and Methods
Murine Studies
WT and D6-deficient mice, TPA painting, and histological
analyses have been described previously.16,20 Antibod-
ies were administered at 200 g i.p. per mouse in PBS
every second day throughout the treatment period. In all
experiments, five mice per group were used, and histol-
ogy was scored by microscopically measuring 20 skin
thicknesses per skin section.
Patient-Based Studies
Uninvolved biopsy samples were obtained from healthy
skin at least 8 cm distant from neighboring psoriatic
plaques. Lesional and peri-lesional biopsy samples were
obtained from single elliptic biopsy samples collected at the
margins of plaques. These elliptic biopsy samples were
halved, with half designated as peri-lesional and the other
half as lesional, using histological criteria. For the tape-
stripping studies (using Scotch tape), patients were sub-
jected to 10 strips of a specific area of skin, and 24 hours
later a biopsy sample was taken from an uninvolved area of
the patient’s body, in addition to a biopsy sample at the site
of tape-stripping. Biopsy samples were immediately placed
on dry ice, RNA was purified, and quantitative polymerase
chain reaction (qPCR) was carried out as described below.
RNA Extraction and qPCR
RNA was purified from primary human epidermal kerati-
nocytes (HEKs) and skin biopsies and qPCR performed
as previously described.15 D6 RNA levels were normal-
ized to GAPDH, TBP, or -actin. Apart from GAPDH,15 the
qPCR primer sequences were as follows: murine, D6-5=-TTCTCCCACTGCTGCTTCAC-3= and 5=-TTCCATCTCAA-
CATCACAGA-3=; human, D6-5=-CTCAGCCATCAGCAGCA-
TT-3= and 5=-GCAAGTGAAGAAAGTGGAGGA-3=; -actin, 5=-
TAAAAACTGGAACGGTGAAGG-3= and 5=-ATTGTGAA-
CTTTGGGGGATG-3=; TBP, 5=-ACTGACCCCACAGCCTA-
TTC-3= and 5=-TGCCTTTGTTGCTCTTCCA-3=.
Immunofluorescence
Biopsy samples were embedded in paraffin and 5-m
sections cut onto superfrost slides (VWR, Leicester, UK),
dewaxed, and rehydrated using xylene and decreasing
ethanol concentrations. Endogenous peroxidase activity
was blocked by incubating sections for 30 minutes in 1%
hydrogen peroxide. Slides were then briefly washed
(PBS-Tween20 (0.05%)) and antigens unmasked by boil-
ing sections for 15 minutes in 0.01 mol/L citric acid, pH 6.
Once sections cooled, they were washed (PBS-Tween20
[0.05%]) and blocked (40 minutes) using 20% equine se-
rum in PBS-Tween20 (0.05%) containing avidin block.
Slides were washed with PBS-Tween20 to remove excess
avidin blocker and then incubated (4°C) with 0.5 g/mL
rabbit–anti-human D6 antibody (Sigma-Aldrich, Poole, Dor-
set) in Real Antibody Diluent (DAKO, Cambridgeshire,
UK) containing 2.5% equine serum, 2.5% human serum,
and biotin block. The next day, sections were washed
with PBS-Tween20 (0.05%) and incubated for 30 minutes
with biotinylated anti-rabbit secondary antibody (Vector
Labs, Peterborough, UK) before further washes in PBS-
Tween20 (0.05%) and incubation for 40 minutes with
FITC-conjugated avidin (Vector Labs). After a final wash
in PBS-Tween20 (0.05%), slides were mounted using
Vectashield containing DAPI and then imaged. CCL2
staining used a monoclonal mouse anti-human CCL2 an-
tibody (R&D Systems, Minneapolis, MN) and a biotinyl-
ated horse anti-mouse secondary antibody (Vector
Labs). CCL5 staining used a polyclonal goat anti-human
CCL5 antibody (R&D Systems) and a biotinylated horse
anti-goat secondary antibody (Vector Labs).
Human Keratinocyte Culture and Cytokine
Stimulations
HEKs were obtained from PromoCell (Heidelberg, Germany),
seeded into 25-cm tissue culture flasks, and fed every sec-
ond day. Before cytokine stimulation, HEKs were seeded
into 12-well plates and allowed to grow to 80% confluency.
Results
D6 Is Involved in the Resolution of Cutaneous
Inflammatory Responses
Exposure of D6-deficient mice to a variety of cutaneous
insults, including dermal liposome injections (Figure 1A)
and subcutaneous granuloma induction (Figure 1B), con-
sistently led to the development of psoriasiform epider-
mal hyperplasia, which was not seen in similarly treated
WT mice and which was identical to that seen after TPA
application to D6-deficient skin. Notably, the psoriasiform
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was responsive to a variety of immune-mediated inter-
ventions including glucocorticoids, TNF blockade,16 an-
tibodies to IL-1, and IL-17; and a receptor-based IL-15-
blocker21 (Figure 1C; see also Supplemental Figure S1 at
http://ajp.amjpathol.org). Together with our previous
data,16 these observations support the notion that D6 is a
central determining factor of inflammatory outcome on
cutaneous provocation.
D6 Is Markedly Overexpressed in Uninvolved
Skin from Psoriatic Patients
Given the association of D6 deficiency with development
of psoriasis-like pathology in murine skin,16 we hypothe-
sized a role for D6 in suppressing chemokine function,and thus lesion development, in human psoriasis. qPCR
analysis of D6 expression in uninvolved, perilesional, and
lesional skin in comparison to healthy control (control)
skin, surprisingly revealed that uninvolved, histologically
normal skin from psoriatic patients displayed markedly
higher D6 expression than control skin (Figure 2A). Ele-
vated expression also was evident in perilesional and
lesional, compared to control, skin, but these levels were
significantly lower than in uninvolved skin (Figure 2A).
Although D6 levels were higher in skin from patients with
atopic dermatitis (Figure 2B), these differences did not
reach statistical significance. Examination of matched
uninvolved/lesional biopsy samples from individual pso-
riatic patients revealed (Figure 2C) elevated expression
in uninvolved, compared with lesional, skin in all but one
patient, suggesting this to be a generalizable phenome-
Figure 1. Dynamic D6 expression is associated with psori-
asis. A: D6-deficient mice displayed psoriasis-like lesions
after repeated liposome injection into tail skin as compared
with WT mice. The Mice were subjected to injections every
second day, and tissue was collected for histology at day 21.
Note the markedly increased epidermal thickening (arrow)
and dermal inflammatory infiltrate (asterisk) in D6-deficient
skin. Scale bar  100 m. B: A psoriasis-like phenotype
(arrow) is seen in D6-deficient mice after subcutaneous
injection of complete Freund’s adjuvant (CFA). CFA was
injected subcutaneously into WT and D6-deficient mice, and
skin was harvested for histology 3 days later. Scale bar 200
m. C: The psoriasis-like pathology developing in D6-defi-
cient mice in response to TPA application is sensitive to
topical hydrocortisone treatment and systemic treatment
with antibodies to IL-1 and IL-17 and a receptor-based
blocker of IL-15. Scale bar  100 m.
Figure 2. D6 is highly expressed and is coincident with
inflammatory CC-chemokines in the epidermis of ‘unin-
volved’ psoriatic skin. A: Relative expression of D6 in unin-
volved, perilesional and lesional psoriatic skin compared
with healthy control (control) skin which is set as the com-
parator of 1. P  0.02 between control and uninvolved, P 
0.003 between uninvolved and both perilesional and le-
sional, and P  0.03 between control and both perilesional
and lesional expression. B: Expression of D6 in biopsy sam-
ples from healthy control skin and lesional atopic dermatitis
skin. C: Expression levels of D6 in matched uninvolved
(open bars) and lesional (filled bars) biopsy samples from 10
patients. D: Immunofluorescent detection of D6 expression
(arrowed) in control, uninvolved, perilesional, and lesional skin
(scale bar 100 m). E: Immunofluorescent detection of CCL2
(arrowed) in control, uninvolved, perilesional, and lesional skin
(scale bar  100 m).
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normal-looking uninvolved skin of psoriatic patients.
D6 Is Prominently Expressed in Uninvolved
Psoriatic Epidermis
Next we characterized cutaneous D6 protein expression
to see if it mirrored the transcriptional data, and to define
the cell types responsible for elevated D6 expression in
uninvolved skin. We demonstrated for the first time that
D6 is expressed in the epidermis in control skin (Figure
2D). This expression is sparse and is restricted to kera-
tinocytes occupying the epidermal basal layer. Consis-
tent with the qPCR data, D6 protein was detectable
throughout the viable epidermal layers in uninvolved pso-
riatic skin. This expression was reduced in perilesional
areas where it was again restricted to the basal layer;
although, its expression in this region was more uniform
than in control epidermis. Intriguingly, in lesional skin, D6
protein expression was again evident throughout all via-
ble epidermal layers. However, this may reflect the un-
coupling of differentiation seen in psoriatic epidermis,
and thus represent expanded basal layer expression,
rather than expression in differentiated layers as seen in
uninvolved skin. Overall, these data demonstrate mark-
edly elevated D6 expression in histologically normal, un-
involved, skin of psoriatic patients.
Elevated D6 Expression Is Coincident with
Inflammatory Chemokine Expression
Elevated D6 expression in uninvolved skin suggests that
it may play a protective role against lesion development
by blocking local chemokine action. We therefore exam-
ined expression of the inflammatory chemokines CCL2
(Figure 2E) and CCL5 (see Supplemental Figure S2 at
http://ajp.amjpathol.org), both of which are high-affinity
D6 ligands,9 in patient samples. Notably, whereas CCL2
(Figure 2E) is undetectable in control skin, it is easily seen
in the upper epidermal layers of uninvolved skin but is not
associated with plaque development at these sites. In
addition, CCL2 is seen in perilesional epidermis and at
extremely high levels in lesional epidermis, where it is
associated with plaque development. D6 and CCL2 show
significant co-localization in lesional epidermis (see Sup-
plemental Figure S3 at http://ajp.amjpathol.org). However
it is also notable that D6 expression predominates in
basal layer keratinocytes whereas CCL2 expression is
maximal in upper epidermal layers. These observations
support the notion that D6 presents a chemokine-scav-
enging barrier between the inflamed outer epidermis and
the dermis. Together these data reveal a correlation be-
tween high levels of D6 expression and the presence, but
apparent lack of function of, inflammation-promoting
chemokine activity in uninvolved psoriatic skin. Impor-
tantly, we have previously reported that enforced epider-
mal D6 expression, in transgenic mice,20 suppresses
cutaneous inflammatory responses. This, along with the
coincidence of chemokine and D6 expression in unin-
volved psoriatic skin, suggests that D6 is elevated inuninvolved skin to block initiation of chemokine-driven
inflammatory responses.
D6 Is Overexpressed in Other Inflammation-
Exposed Cells in Psoriatic Patients
To determine whether D6 overexpression was restricted
to uninvolved epidermis or whether it was also seen in
other cell types, we evaluated expression in more typical
D6-expressing cells ie, dermal lymphatic vessels12 and
peripheral blood leukocytes (PBLs).15 D6 expression in
lymphatic vessels was enumerated by counting the num-
bers of D6/podoplanin dermal vessels, per total
podoplanin vessels in skin sections. As with the epider-
mal expression, markedly upregulated D6 expression
was seen in lymphatic vessels in uninvolved psoriatic
skin, compared with control, or perilesional or lesional
skin (Figure 3A). In addition, we found similarly upregu-
lated D6 expression in PBLs of psoriatics compared with
controls (Figure 3B). Together these observations sug-
gest that elevated D6 expression may be a general pro-
tective cellular response to inflammation in psoriatics and
that the elevated expression seen in uninvolved skin is a
combination of increased epidermal and lymphatic D6
transcript numbers.
Cutaneous D6 Expression Is Regulated by
Psoriasis-Relevant Cytokine Activity and Trauma
Next we examined the basis for the upregulated D6 ex-
Figure 3. D6 is expressed by a range of cell types in psoriatic patients. A:
Enumeration of D6/podoplaninlymphatic vessels in the dermis of control
and psoriatic skin biopsy samples. Levels in uninvolved skin are significantly
higher (*P  0.0001) than in control, perilesional, or lesional skin. B: qPCR
analysis of D6 expression in control and psoriatic peripheral blood leuko-
cytes. *P  0.0001.pression in uninvolved psoriatic epidermis by measuring
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D6 expression. Microarray and other studies show that
unaffected psoriatic skin differs from control skin in ex-
pression of pro-inflammatory cytokines22,23 including IL-
1. In addition, although plasmacytoid dendritic cells
(pDCs) are absent from control skin, they are seen in both
uninvolved and involved psoriatic skin.24 pDCs produce
type I inteferons (IFNs), which play prominent roles in
psoriasis pathogenesis. Notably, both IL-1 (Figure 4A)
and IFN- (Figure 4B) induced significant increases in D6
transcript levels in vitro (and protein levels, shown for
IFN-; Figure 4C) in cultured keratinocytes. The differ-
ences in D6 transcript levels induced by these cytokines
were modest but suggested up-regulation by inflamma-
tory cytokines. To examine this in more detail, we tested
additional cytokines for their ability to affect D6 expres-
sion. As shown in Figure 4D, and similar to the data
presented for IL-1 and interferon-, TNF induced signif-
icant but modest increases in D6 expression at all time
points tested and IL-1 induced a significant enhance-
ment of D6 expression by 48 hours. Strikingly, however,
IFN- induced significant and substantial D6 overexpres-
sion ( 20-fold by 48 hours) at all time points measured.
Furthermore, treatment of keratinocytes with a mix of in-
flammatory cytokines (see Supplemental Figure S4 at
http://ajp.amjpathol.org) induced even stronger transcrip-
tional up-regulation ( 35-fold). Intriguingly, neither IL-17
nor IL-22 had any effect on D6 transcript levels despite
their known involvement in psoriasis pathogenesis. We
therefore propose that a major proportion of elevated D6
expression in uninvolved psoriatic skin results from in-
flammatory cytokine expression in this area.
Finally, we examined the possible basis for the transi-
tion from high to low D6 expression in uninvolved and
perilesional skin, as this may prove permissive to inflam-
mation onset. In some psoriatic patients, a phenomenon
called Koebnerisation1 is observed in which trauma to
uninvolved skin leads to lesion development, suggestingthat uninvolved skin is primed for lesion formation, which
is in keeping with the observation of expression of inflam-
matory chemokines in this apparently normal-looking
skin. These observations raise the possibility that trauma
may trigger plaque development in part by reducing D6
expression and thus unmasking chemokine activity in the
skin. We therefore induced mild trauma in uninvolved
psoriatic skin by tape stripping. Twenty-four hours later,
we obtained a full-thickness skin biopsy sample from the
traumatized area as well as a second biopsy sample from
the same patient from a nontraumatized, uninvolved skin
area. As can be seen in Figure 4E (left panel), trauma to
uninvolved psoriatic skin significantly reduced D6 ex-
pression by 24 hours, supporting a role for mild tissue
trauma in the suppression of D6 expression and the tran-
sition from uninvolved to lesional skin. This reduction in
D6 transcript levels was also reflected in reduced D6
immunostaining in traumatized epidermis 48 hours after
tape stripping (Figure 4E, right panels).
Thus differential D6 expression within psoriatic skin
can be partly explained on the basis of psoriasis-relevant
cytokine activity and trauma supportive of a role in sup-
pressing lesion development.
Discussion
The identification and characterization of the inflamma-
tory chemokine “scavenging” receptor D6 has shed new
light on the overall regulation of the resolution phase of
inflammatory responses.7 Through its ability to efficiently
internalize, and degrade, inflammatory CC chemokines,
D6 plays an indispensable role in the resolution of inflam-
matory responses at each of the body sites at which it is
expressed. Our previous studies have demonstrated that
D6-deficient mice respond to inflammation induced by
phorbol ester by developing a psoriasiform pathology.16
Figure 4. D6 expression is regulated by psoriasis-relevant
cytokines and trauma. IL-1 (A) and IFN- (B) induce up-
regulation of D6 expression in cultured keratinocytes in vitro
at 6 hours (IL-1) and 48 hours (IFN-), respectively. Cyto-
kines were used at 100 ng/mL. C: D6 protein levels were
assessed as the number of D6 cells per 20 microscopic
field and 10 fields were counted for control and for IFN-–
treated cell monolayers (left panel). Immunofluorescent
staining demonstrates elevated D6 protein expression in
IFN-–treated compared with PBS-treated keratinocytes
(right panels). D: Keratinocytes were treated with each of
the indicated cytokines at 100 ng/mL for 6, 24, or 48 hours,
and D6 expression levels were assessed by q-PCR. *P 0.03;
**P  0.01; ***P  0.002. E: Trauma induced by tape strip-
ping causes a significant reduction in D6 transcript expres-
sion in full-thickness skin biopsy samples from “uninvolved”
psoriatic skin by 24 hours, compared with expression in
similar biopsy samples from nontraumatized uninvolved
skin from the same donors (left panel), and (right panels)
intensity of D6 immunostaining in biopsy samples from trau-
matized compared with matched, nontraumatized unin-
volved skin at 48 hours Scale bar  100 m.Here we show that this psoriasis-like response is a com-
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ficient mice exposed to varied inflammatory stimuli. The
remarkable similarity of the cutaneous pathology in in-
flamed D6-deficient skin to human psoriasis led us to
examine the possible involvement of D6 in the pathogen-
esis of this disorder. We now report that D6 is markedly
overexpressed in the epidermis and lymphatic endothe-
lium of uninvolved compared with lesional skin of psori-
atic patients as well as healthy control skin. This is coin-
cident with elevated, but apparently nonfunctional,
inflammatory CC-chemokine expression in the unin-
volved areas. We have previously shown that when D6 is
transgenically expressed in the murine epidermis, it can
impair the development of cutaneous inflammatory re-
sponses to topically applied inflammatory stimuli.20
Therefore, the elevated D6 expression in uninvolved skin
epidermis is compatible with a role in the local suppres-
sion of inflammatory chemokine action, and a block to
psoriatic lesion development, at these sites.
D6 transcript levels are lower in perilesional and le-
sional psoriatic skin; although, as in uninvolved skin,
strong D6 immunostaining is seen in lesional epidermis
(presumably induced by the numerous inflammatory cy-
tokines present at these sites), suggesting that LEC ex-
pression of D6 may significantly contribute to the relative
elevation of transcript levels in uninvolved skin. Of nota-
ble interest is the observation that mild trauma, in the form
of tape stripping, is able to bring about a reduction in
cutaneous D6 expression. Tape stripping was selected to
mimic the Koebner phenomenon,1 in which mild trauma
to otherwise healthy skin of psoriatic patients can precipi-
tate the development of lesions. Our data suggest that a
trauma-induced down-regulation of D6 expression may
contribute to lesion development, and explain in part the
Koebner phenomenon and the transition from uninvolved to
lesional skin. We propose that whereas epidermal D6 ex-
pression is again elevated at lesional sites, it is not sufficient
to fully control the now-established inflammatory response.
Intriguingly, not only is D6 elevated in the epidermis
and lymphatic endothelium in uninvolved skin, it is also
markedly elevated in PBLs, indicating that elevated D6
expression is a generic response in patients to inflamma-
tion and one that is designed to suppress pathological
inflammatory responses. Our observations of elevated D6
expression in the PBLs of systemic sclerosis patients and
the demonstration of an inverse correlation between D6
expression and circulating inflammatory CC chemokine
levels support this contention.25 Further analysis of PBLs
in both psoriasis and systemic sclerosis indicates that D6
expression is elevated in all leukocyte subtypes, and that
this elevation is not accounted for by increases in any par-
ticular leukocyte subpopulations (25) (data not shown).
To conclude, we have demonstrated for the first time
that D6 is overexpressed in a range of cell types in
psoriatic patients. In uninvolved psoriatic skin, expres-
sion is coincident with inflammatory CC chemokine ex-
pression and consistent with a role in suppressing
chemokine-driven inflammatory responses. We suggest
that where D6 expression drops in perilesional areas or
after trauma, inflammatory chemokines can gain a “foot-
hold” and establish inflammatory responses leading toplaque formation. We therefore propose a role for D6 as
a novel suppressor of psoriasis pathogenesis, and sug-
gest that regulation of D6 expression within psoriatic skin
may be a viable therapeutic option.
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